<DOC>
	<DOCNO>NCT00374322</DOCNO>
	<brief_summary>This study design evaluate compare safety efficacy oral dual tyrosine kinase inhibitor , lapatinib , versus placebo woman early-stage ErbB2-overexpressing breast cancer complete primary neoadjuvant adjuvant chemotherapy clinical radiographic evidence disease .</brief_summary>
	<brief_title>Tykerb Evaluation After Chemotherapy ( TEACH ) : Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Have histologically cytologically confirm ErbB2overexpressing invasive carcinoma ( TX T14 ) breast time initial diagnosis undergone adequate excision tumor ; Had tumor overexpress ErbB2 define 3+ IHC cerbB2 gene amplification FISH ( ErbB2 expression/amplification must document prior study entry ; however , tumor tissue sample must send central laboratory subsequent reanalysis ErbB2 status ) ; Have Stage I Stage IIIc disease accord American Joint Committee Cancer ( 6th edition ) stag criterion breast cancer meet one follow criterion : nodepositive disease define : one positive lymph node sentinel node biopsy OR least 1 positive lymph node find among least 6 axillary node examine axillary node dissection OR status post axillary radiotherapy sterilization clinically evaluate cN1 cN2 ( sentinel node biopsy positive , subject may either undergo axillary node dissection radiotherapy axilla ) . nodepositive disease evaluate : ipsilateral axillary lymph node cN02 clinical evaluation axillary lymph node pNX , pN0 ( i+ ) , pN13 pathological evaluation [ patient pN3 ( Stage IIIc disease ) must disease free follow completion neoadjuvant adjuvant chemotherapy least 12 month must lose follow ] . OR nodenegative disease define : negative sentinel node biopsy OR positive lymph node find among least 6 axillary node examine axillary node dissection OR status post axillary radiotherapy sterilization clinically evaluate cN0 . nodenegative disease categorize : highrisk disease ( tumor &gt; 2.0 cm ER and/or progesterone receptor ( PgR ) positive disease present tumor &gt; 1.0 cm ER PgR negative disease ) OR intermediaterisk disease ( tumor 1.02.0 cm ER and/or PgR positive disease ) . Women synchronous bilateral invasive breast cancer synchronous DCIS either contralateral ipsilateral breast time initial diagnosis also eligible ; Have undergone either mastectomy OR lumpectomy ; Have receive complete treatment neoadjuvant adjuvant chemotherapy regimen contain either anthracycline taxane ; cyclophosphamide , methotrexate 5fluorouracil ( CMF ) regimen ; May continue receive endocrine therapy take study medication , endocrine therapy initiate either adjuvant therapy treatment initial diagnosis invasive breast cancer ovarian function suppression ; however , endocrine therapy may initiate take study medication . Endocrine therapy agent may switch participate study ( e.g. , stop tamoxifen start letrozole ) ; May receive prior radiotherapy treatment primary tumor ; however , require study entry ; May continue receive radiotherapy take study medication , radiotherapy initiate adjuvant therapy treatment initial diagnosis invasive breast cancer ; May continue receive bisphosphonates treatment document osteoporosis , treatment prophylaxis bone metastasis ; All woman eligible adjuvant treatment trastuzumab , include diagnose treat within last six month , must consider treatment prior offer participation study . Participation study allow physician patient consider discussed length advantage trastuzumab , mutually decide initiate trastuzumab therapy . Have clinical radiologic assessment negative local regional recurrence disease metastatic disease time study entry ; sign symptoms suggestive either recurrence disease metastatic disease present , appropriate radiological imaging must perform follow laboratory result present , appropriate radiological imaging must perform : AST/ALT ≥2×ULN ALP ≥2×ULN ( bone fraction ) , abdominal CT MRI must do ALP≥2×ULN bone fraction , bone scan must do ; confirmatory xray , CT scan MRI scan biopsy require result bone scan inconclusive Have unilateral/bilateral mammogram within 12 month prior study entry ; Have analysis ER PgR primary tumor prior study entry ; Have cardiac ejection fraction within institutional range normal measure either echocardiogram multigated acquisition scan ; Have Eastern Cooperative Oncology Group Performance Status 0 1 ; Women history nonbreast malignancy eligible diseasefree least 5 year deem investigator low risk recurrence . Women follow cancer eligible diagnose treat within past 5 year : cervical carcinoma situ , melanoma situ , basal cell squamous cell carcinoma skin ; Are able swallow retain oral medication ; Have paraffinembedded tissue block archive tumor tissue primary tumor twenty ( 20 ) slide paraffinembedded tissue available biomarker analysis ; Have adequate organ function define : absolute neutrophil count ≥1.5× 10^9/L ; hemoglobin ≥9 g/dL ; platelet ≥75 × 10^9/L ; albumin ≥2.5 g/dL ; serum bilirubin ≤1.25 ×ULN ; aspartate aminotransferase alanine aminotransferase ≤3 × ULN serum creatinine ≤2.0 mg/dL calculate creatinine clearance ≥40 mL/min Have sign inform consent form ( ICF ) ; Women childbearing potential must negative serum pregnancy test screen agree complete abstinence intercourse consistent correct use acceptable method birth control 2 week prior administration first dose study medication 28 day final dose study medication : Have clinical radiologic evidence local regional recurrence disease metastatic disease time study entry ; Had metachronous invasive breast cancer ( breast cancer diagnose different time ) ; Have prior history breast cancer malignancy , include DCIS ; Are unable provide archive tumor tissue sample assay ; Had prior therapy ErbB1 and/or ErbB2 inhibitor ; woman experience hypersensitivity allergic reaction trastuzumab first infusion unable complete infusion eligible ; Receive concurrent anticancer therapy ( chemotherapy , immunotherapy , biologic therapy ) take study medication ; Have unresolved unstable , serious toxicity prior administration another investigational drug and/or prior cancer treatment ; Have malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . Women ulcerative colitis also exclude ; Have concurrent disease condition would make woman inappropriate study participation , serious medical disorder would interfere woman 's safety ; Have active uncontrolled infection ; Have dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent ; Have know history uncontrolled symptomatic angina , arrhythmia , CHF ; Are pregnant breastfeeding ; Receive concurrent treatment investigational agent ; woman , followup another clinical trial primary endpoint meet interval assessment ≥12 month radiological imaging required assessment , eligible ; Receive concurrent treatment select list strong inducer inhibitor CYP3A4 ; Used investigational drug within 30 day 5 halflives , whichever longer , precede first dose study medication ; Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate lapatinib excipients ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>ErbB2-overexpressing</keyword>
	<keyword>early-stage breast cancer</keyword>
	<keyword>adjuvant</keyword>
</DOC>